• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, September 20, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Good news for kids with epilepsy

Bioengineer by Bioengineer
February 27, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

MINNEAPOLIS – There's good news for kids with epilepsy. While several new drugs have come out in the last several years for adults with epilepsy, making those drugs available for children and teenagers has been delayed due to the challenges of testing new drugs on children. But an analysis of all the research published on adults and children shows that the positive results seen in adults appear to be similar in children. The preliminary meta-analysis was released today and will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.

"The results of this analysis may bring new hope for children and teens with epilepsy and their families," said Douglas R. Nordli, Jr., MD, of Children's Hospital Los Angeles in Los Angeles, Calif., and a member of the American Academy of Neurology.

The analysis evaluated only studies of people with primary generalized tonic-clonic seizures. Tonic-clonic seizures are what people typically think of as a seizure. They involve loss of consciousness, stiffening of muscles and jerking movements. Primary generalized seizures means the whole brain is affected.

For the analysis, researchers analyzed all randomized, placebo-controlled trials of drugs for this type of seizure in adults and children published from 1970 to 2015. The studies were looking at drugs that are taken in combination with another epilepsy medication.

Seven studies were found that met the criteria, one study on children, two on both adults and children and four on adults. The researchers looked at the average percentage reduction in seizure frequency and the percentage of people whose seizures were reduced by 50 percent or more. For the studies in adults, the results were extrapolated to estimate the effect on children.

The analysis showed that the effectiveness of the medicines was similar in adults and children and the effectiveness of the drugs did not depend on the age of the patient.

"The results consistently showed that the epilepsy drug was beneficial compared to the placebo, and the results were comparable between adult and pediatric groups," Nordli said. "Since only about 50 percent of kids become seizure free after trying their first medication, it's vitally important to have additional options for kids so they can get back to being kids."

###

The study was supported by Eisai, Inc.

Learn more about epilepsy at http://www.aan.com/patients.

The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with 32,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+, LinkedIn and YouTube.

Media Contact

Renee Tessman
[email protected]
612-928-6137

Michelle Uher
[email protected]
612-928-6120

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Next-Gen Oncology: Precision Genomics Meets Immuno-Engineering

September 20, 2025

Prostate-Specific Antigen Testing: Past, Present, Future

September 20, 2025

Bisabolol: Natural Anticancer Agent with Therapeutic Promise

September 20, 2025

VDAC1 Analysis and Natural Inhibitors in Gynecological Tumors

September 20, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    67 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    48 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Next-Gen Oncology: Precision Genomics Meets Immuno-Engineering

Prostate-Specific Antigen Testing: Past, Present, Future

Bisabolol: Natural Anticancer Agent with Therapeutic Promise

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.